{"entity":{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","aka":["Hypericin","SGX301","Hypericin ointment"],"tldr":"HyBryte is an ointment containing synthetic hypericin, the active pigment of St John's wort. Rubbed on patches of cutaneous T-cell lymphoma and switched on with ordinary visible light, it kills the lymphoma cells in the skin without ultraviolet light.","summary":"Synthetic hypericin (SGX301, HyBryte) is Soligenix's photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides). The ointment is applied to lesions and, after a delay, the area is exposed to visible fluorescent light twice a week. Because activation uses visible rather than ultraviolet light, the treatment avoids the skin-cancer and ageing risks of long-term PUVA and narrow-band UVB.\n\nThe phase 3 FLASH trial reported in 2020 that significantly more patients had a treatment response after the first 6-week cycle than with placebo ointment, and responses increased with longer treatment. The FDA asked for a second confirmatory study before approval, and the confirmatory FLASH2 trial is under way. The cutaneous T-cell lymphoma page names it as the skin-directed treatment closest to approval.","status":"phase-3","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Hypericin","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hypericin"}],"tags":["subtype-drugs-wave"],"related":[],"cancers":["cutaneous-t-cell-lymphoma"],"sections":[],"technologies":["photodynamic-therapy-lasers"],"targets":[],"drugs":[],"companies":["soligenix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"HyBryte","code":"SGX301","modality":"Topical photosensitiser activated by visible light","mechanism":"Hypericin, the pigment of St John's wort made synthetically, is applied to skin lesions and taken up by malignant T cells; visible light then activates it to generate reactive oxygen that kills the cells, without the ultraviolet exposure of PUVA.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hypericin-sgx301/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"}],"technology":[{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/"}],"company":[{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/"}]}}